Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

801 participants

Study Classification

OBSERVATIONAL

Study Start Date

2001-07-31

Study Completion Date

2005-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to compare the efficacy and tolerance of piperacillin-tazobactam versus piperacillin-tazobactam plus glycopeptide as initial empiric antibiotic treatment for fever in neutropenic patients. Study of consecutive cohorts(2). First the patients will be included in the monotherapy branch until completing the predicted number of cases. When this happens, the Coordinating Center will communicate it to the participant centers and from then the patients will be included in the combined therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections

NCT05355350

Beta Lactam Resistant Bacterial Infection Enterobacteriaceae Infections Bacteremia

WITHDRAWN PHASE4

PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)

NCT03671967

Beta Lactam Resistant Bacterial Infection Enterobacteriaceae Infections Bacteremia

RECRUITING PHASE4

Piperacillin/Tazobactam for Bacteremia With Organisms Producing Chromosomally-Encoded AmpC Beta-Lactamase

NCT00414193

Bacteremia AmpC Beta-lactamase

COMPLETED

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

NCT00167999

Gram-Positive Bacterial Infections Escherichia Coli Infections Klebsiella Infections

COMPLETED

Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.

NCT00195286

Urinary Infections

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematological Malignancy Leukemia Myelodysplasia Lymphoma Myeloma Stem Cell Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

piperacillin-tazobactam

Intervention Type DRUG

glycopeptide

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with hematological malignancy or those who had undergone stem cell transplantation for neoplastic disease.
* Fever (\>38ºC)
* Neutropenia (absolute neutrophil count \< 500 or \< 1000 anticipated to fall below 500 cells within 24-48 hours).